Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Etilamfetamine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Ethylamphetamine
INN: Etilamfetamine
Ball-and-stick model of etilamfetamine molecule
Clinical data
Trade namesApetinil; Adiparthrol
Other namesEtilamfetamine; Ethylamphetamine;N-Ethylamphetamine; PAL-99; PAL99
Routes of
administration
Oral,sublingual,insufflated, inhaled (vaporized),intravenous,rectal
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic (N-dealkylation, others)[2]
MetabolitesAmphetamine[2]
ExcretionUrine (5–18% asamphetamine)[2]
Identifiers
  • N-Ethyl-1-phenyl-propan-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.230.711Edit this at Wikidata
Chemical and physical data
FormulaC11H17N
Molar mass163.264 g·mol−1
3D model (JSmol)
  • N(C(Cc1ccccc1)C)CC
  • InChI=1S/C11H17N/c1-3-12-10(2)9-11-7-5-4-6-8-11/h4-8,10,12H,3,9H2,1-2H3 checkY
  • Key:YAGBSNMZQKEFCO-UHFFFAOYSA-N checkY
  (verify)

Etilamfetamine, also known asN-ethylamphetamine and formerly sold under the brand namesApetinil andAdiparthrol, is astimulant drug of theamphetamine family. It was invented in the early 20th century and was subsequently used as ananorectic orappetite suppressant in the 1950s,[3] but was not as commonly used as other amphetamines such asamphetamine,methamphetamine, andbenzphetamine, and was largely discontinued once newer drugs such asphenmetrazine were introduced.

Pharmacology

[edit]

Pharmacodynamics

[edit]

Monoamine releasing agent

[edit]

Ethylamphetamine is apotentdopamine releasing agent (DRA)in vitro, with anEC50Tooltip half-maximal effective concentration of 88.5 nM.[4] This is about 10-fold lower than theEC50 ofdextroamphetamine.[4] TheEC50 values of ethylamphetamine for induction ofnorepinephrine andserotonin release were not reported.[4] However, theEC50 values of itsdextrorotatoryenantiomer dextroethylamphetamine have been reported and were 44.1 nM, 28.8 nM, and 333 nM for norepinephrine, dopamine, and serotonin, respectively.[5][6] Hence, dextroethylamphetamine acts as anorepinephrine–dopamine releasing agent (NDRA) with weak effects on serotonin.[5][6]

In terms ofstructure–activity relationships, the potency of amphetamines asdopamine releasing agents andreuptake inhibitors decreases with increasingN-alkylchain length.[4] That is, the order of potency ofN-alkylated amphetamines is as follows:amphetamine >methamphetamine > ethylamphetamine >propylamphetamine >butylamphetamine.[4] Propylamphetamine is a weak dopamine reuptake inhibitor rather than releaser, whereas butylamphetamine is completely inactive as a dopamine releaser or reuptake inhibitor.[4] The same relationship, formonoamine release andreuptake inhibition generally, has been shown with4-methylamphetamine and itsN-alkylated derivatives like4-methylmethamphetamine and so forth.[7][8]

Monoamine release ofethylamphetamine and related agents (EC50Tooltip Half maximal effective concentration, nM)
CompoundNETooltip NorepinephrineDATooltip Dopamine5-HTTooltip SerotoninRef
Phenethylamine10.939.5>10,000[4][9][10]
d-Amphetamine6.6–10.25.8–24.8698–1,765[11][12][10][13]
d-Methamphetamine12.3–14.38.5–40.4736–1,292[11][14][10][13]
EthylamphetamineND88.5ND[4]
  d-Ethylamphetamine28.844.1333.0[5][6]
PropylamphetamineNDRI (1,013)ND[4]
ButylamphetamineNDIA (>10,000)ND[4]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. Theassays were done in rat brainsynaptosomes and humanpotencies may be different. See alsoMonoamine releasing agent § Activity profiles for a larger table with more compounds.Refs:[15][16]

Other actions

[edit]

Ethylamphetamine is inactive as an agonist of the mouse and humantrace amine-associated receptor 1 (TAAR1), whereas findings in the case of the rat TAAR1 are conflicting.[17][18] In one study, its Ki was 2,500 nM and itsEC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) was 880 nM (62%) at the rat TAAR1 (i.e., it was apartial agonist), whereas its Ki and/orEC50 values at the mouse and human TAAR1 were >10,000 nM.[17] In another study however, ethylamphetamine showed very little capacity to activate the rat TAAR1.[17]

Pharmacokinetics

[edit]

Ethylamphetamine can beN-dealkylated intoamphetamine (5–18%excreted inurine after 24 hours).[2] As such, amphetamine may contribute to its effectsin vivo.[2]

Chemistry

[edit]

Themolecular structure of ethylamphetamine isanalogous tomethamphetamine, with anethyl group in place of themethyl group.[Note 1] It can also be considered asubstituted amphetamine, with an ethyl group on the amphetamine backbone.[Note 2][Note 3]

Analogues of ethylamphetamine include amphetamine, methamphetamine,propylamphetamine,isopropylamphetamine,butylamphetamine,fenfluramine (3-trifluoromethyl-N-ethylamphetamine),dimethylamphetamine, and3-fluoroethamphetamine (3-fluoro-N-ethylamphetamine), among others.

Society and culture

[edit]

Recreational use

[edit]

Ethylamphetamine can be used as arecreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though it is of lowerpotency.[citation needed]

Notes

[edit]
  1. ^Amphetamine is a substituted phenethylamine with amethyl group at RA position.
  2. ^Theethyl group of ethylamphetamine is at RN position, hence the nameN-ethylamphetamine.
  3. ^Ethylamphetamine is structurally similar toN-methylamphetamine (methamphetamine), theethyl group being replaced in methamphetamine with amethyl group.

References

[edit]
  1. ^Anvisa (2023-03-31)."RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-04-04).Archived from the original on 2023-08-03. Retrieved2023-08-16.
  2. ^abcdeBeckett AH, Shenoy EV (October 1973). "The effect of N-alkyl chain length of stereochemistry on the absorption, metabolism and during excretion of N-alkylamphetamines in man".J Pharm Pharmacol.25 (10):793–799.doi:10.1111/j.2042-7158.1973.tb09943.x.PMID 4151673.
  3. ^Junet R (October 1956). "L'éthylamphétamine dans le traitement de l'obésité" [Ethylamphetamine in the treatment of obesity].Praxis.45 (43):986–988.PMID 13389142.
  4. ^abcdefghijReith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (February 2015)."Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter".Drug Alcohol Depend.147:1–19.doi:10.1016/j.drugalcdep.2014.12.005.PMC 4297708.PMID 25548026.
  5. ^abcFitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE (March 2024)."Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones".Neuropharmacology.245 109827.doi:10.1016/j.neuropharm.2023.109827.PMC 10842458.PMID 38154512.
  6. ^abcNicole, Lauren (2022)."In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones".ProQuest. Retrieved5 December 2024.FIGURE 2-6: Release: Effects of the specified test drug on monoamine release by DAT (red circles), NET (blue squares), and SERT (black traingles) in rat brain tissue. [...] EC50 values determined for the drug indicated within the panel. [...]
  7. ^Solis E, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH (September 2017)."N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability".Neuropsychopharmacology.42 (10):1950–1961.doi:10.1038/npp.2017.98.PMC 5561352.PMID 28530234.
  8. ^Sakloth, Farhana (11 December 2015).Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action.VCU Scholars Compass (Thesis).doi:10.25772/AY8R-PW77. Retrieved24 November 2024.
  9. ^Forsyth, Andrea N (22 May 2012)."Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines".ScholarWorks@UNO. Retrieved4 November 2024.
  10. ^abcBlough B (July 2008)."Dopamine-releasing agents"(PDF). In Trudell ML, Izenwasser S (eds.).Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320.ISBN 978-0-470-11790-3.OCLC 181862653.OL 18589888W.
  11. ^abRothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin".Synapse.39 (1):32–41.doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.PMID 11071707.S2CID 15573624.
  12. ^Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (March 2013)."Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products".Neuropsychopharmacology.38 (4):552–562.doi:10.1038/npp.2012.204.PMC 3572453.PMID 23072836.
  13. ^abPartilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB (1999). "Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substractes".Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc(PDF). NIDA Res Monogr. Vol. 180. pp. 1–476 (252).PMID 11680410. Archived fromthe original(PDF) on August 5, 2023.RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM). [...]
  14. ^Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (April 2012)."The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue".Neuropsychopharmacology.37 (5):1192–1203.doi:10.1038/npp.2011.304.PMC 3306880.PMID 22169943.
  15. ^Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs".European Journal of Pharmacology.479 (1–3):23–40.doi:10.1016/j.ejphar.2003.08.054.PMID 14612135.
  16. ^Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates".Current Topics in Medicinal Chemistry.6 (17):1845–1859.doi:10.2174/156802606778249766.PMID 17017961.
  17. ^abcSimmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016)."In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1"(PDF).J Pharmacol Exp Ther.357 (1):134–144.doi:10.1124/jpet.115.229765.PMID 26791601. Archived fromthe original(PDF) on 2025-05-09.
  18. ^Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor".Mol Pharmacol.60 (6):1181–1188.doi:10.1124/mol.60.6.1181.PMID 11723224.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonists
GLP-1,GIP,and / or
glucagon agonists
DACRAs
5-HT2C
receptor agonists
Absorption inhibitors
Uncouplers
Others
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Etilamfetamine&oldid=1319650105"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp